证券代码：688202 证券简称：美迪西 公告编号：2026-004 二、经营业绩和财务状况情况说明 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以上海美迪西生 物医药股份有限公司（以下简称"公司"）2025年年度的定期报告为准，提请投资者注意投资风险。 上海美迪西生物医药股份有限公司 2025年度业绩快报公告 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.上表中归属于母公司所有者的每股净资产中普通股股数为总股本扣除回购股份数。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 3.以上财务数据及指标以合并报表数据填制，但未经审计，最终数据以公司2025年年度报告中披露的数 据为准。 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、报告期的经营情况、财务状况 报告期内，公司实现营业收入116,113.90万元，同比增长11.89%；实现归属于母公司所有者的净利 润-15,502.00万元，较上年同期亏损减少17,582. ...

格隆汇2月27日丨美迪西(688202.SH)公布2025年度业绩快报，报告期内，公司实现营业收入116,113.90 万元，同比增长11.89%;实现归属于母公司所有者的净利润-15,502.00万元，较上年同期亏损减少 17,582.58万元;实现归属于母公司所有者的扣除非经常性损益的净利润-17,017.07万元，较上年同期亏损 减少17,754.25万元。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，美迪西发布公告称，公司2025年实现营业收入116113.90万元，同比增长 11.89%。 ...

证券代码：688202 证券简称：美迪西 公告编号：2026-004 上海美迪西生物医药股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以上海美迪西生物医药股份有限公司（以下简称"公司"）2025 年年度的定期报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 116,113.90 | 103,774.57 | 11.89 | | 营业利润 | -15,726.71 | -37,516.57 | 不适用 | | 利润总额 | -17,083.57 | -38,107.51 | 不适用 | | 归属于母公司所有者的 | -15,502.00 | -33,084.58 | 不适用 | | 净利润 | | | | | 归属于母公司所有者的 ...

美迪西发布业绩快报，预计2025年营业收入11.61亿元，同比增长11.89%。公司加快全球化战略布局， 充分发挥研发平台资源和优势，提升项目实施及项目交付的效率，公司营业收入实现稳步增长，同比增 长约12%，其中境外主营业务收入占比提升至约47%。公司在推动营业收入增长的同时，持续深化降本 增效，营业成本同比下降，综合毛利率同比提升约11个百分点，盈利能力稳步改善，实现亏损规模大幅 收窄。 ...

Group 1 - The core viewpoint of the news is that the national centralized procurement of medicines is expected to stabilize production and sales expectations in the pharmaceutical industry, with a high selection rate of 93% for the involved drugs [1] - The procurement involves 316 commonly used drugs across 26 treatment areas, including anti-infection and anti-tumor [1] - The procurement process is led by the National Healthcare Security Administration and will follow a unified national rule, with the procurement period extending until the end of 2028 [1] Group 2 - The stock price of Medisi has shown significant volatility in the recent trading days, with a peak increase of 7.20% on February 6, closing at 70.00 yuan [2] - On February 9, the stock price dropped by 4.29% to 67.00 yuan, influenced by market sentiment, followed by a slight increase of 0.28% on February 12, closing at 67.19 yuan [2] - The trading range for the stock during this period reached 21.97%, indicating active trading, with fluctuations in financing balance observed [2]

Core Viewpoint - Medicy's ongoing expansion and operational capabilities in drug research and development are aimed at enhancing its service scale and quality in the pharmaceutical industry [2] Group 1: Company Operations - Medicy has operational research laboratories located in Shanghai Zhangjiang Hi-Tech Park, Chuansha Economic Park, and the South Shanghai Medicy New Drug Innovation Center, as well as a research center in Boston, USA [2] - The main building of the fundraising project "Laboratory Expansion Project for Drug Discovery and Pharmaceutical Research and Application" in the South Shanghai area has completed acceptance, which will further enhance the scale and level of new drug research and development services [2] Group 2: Future Development Strategy - The company will continue to improve the utilization rate of existing production capacity and will advance the construction and use of new capacity in a scientific and orderly manner based on business development and strategic planning [2] - This approach aims to ensure steady future business development and the smooth implementation of projects [2]

Core Viewpoint - The company, Medici, is positioning itself as a leading Contract Research Organization (CRO) by focusing on innovative drug development technologies and enhancing its research capabilities through AI integration [2] Group 1: Innovation and Technology Development - The company is developing a three-in-one innovative technology service platform that includes human cell models, AI predictions, and organoids to enhance drug research [2] - Medici is building a one-stop preclinical research service platform based on AI technology to streamline the drug development process [2] - The company has developed an AI ADMET prediction model to improve the efficiency and success rate of drug development [2] Group 2: Collaboration and Resource Integration - Medici is collaborating with multiple AI-driven drug development companies to establish an AI drug discovery service platform, integrating external technological resources with internal research capabilities [2] - The company's AI-based one-stop preclinical research service platform project has received government approval and is already providing services to clients [2] Group 3: Competitive Advantage - The company aims to continuously enhance its research service capabilities and competitive advantages by exploring the application of relevant technologies in its research business [2]

Core Insights - The price of experimental monkeys in the market is on the rise, indicating a growing demand and potential supply constraints for this specific type of laboratory animal [2] Company Actions - The company is actively taking measures to ensure a stable supply of experimental monkeys by diversifying procurement channels and deepening cooperation with laboratory animal suppliers [2]

Core Viewpoint - Medisi plans to enhance its competitive advantage in preclinical integrated research through continuous development and integration strategies [2] Group 1: Business Strategy - The company aims to deepen its integrated research strategy in preclinical studies [2] - Medisi intends to explore suitable opportunities for expanding its upstream and downstream industry chain based on actual business conditions [2] - The company seeks to align its expansion efforts with its internationalization strategy while strengthening its existing research and development technology platform [2] Group 2: Future Plans - Medisi will supplement or enhance its existing business chain as part of its growth strategy [2] - Any future merger and acquisition plans will be executed in accordance with relevant laws and regulations, ensuring timely decision-making and information disclosure [2]